PALISADE BIO, INC. Debt Conversion, Converted Instrument, Amount
PALISADE BIO, INC. (PALI) reported Debt Conversion, Converted Instrument, Amount of $1.00 million for the 12-month period ending 2014-12-31, per its 10-Q filed 2016-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2016-05-09
- PALISADE BIO, INC. debt conversion, converted instrument, amount for the quarter ending 2014-06-30 was $0.00.
- PALISADE BIO, INC. debt conversion, converted instrument, amount for the quarter ending 2014-03-31 was $1.00M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|
| 2014-12-31 | $1.00M 10-Q · filed 2016-05-09 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $1.00M 10-Q · filed 2015-08-10 | |
| 2014-03-31 | $1.00M 10-Q · filed 2015-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |